SL Science Holding Limited (SLBT) experienced a sharp rebound in early trading on Tuesday, with shares soaring to $18.90 on Robinhood after a tumultuous first day on the Nasdaq. The stock had plunged 42.59% on Monday, closing at $3.33, as the market reacted to the company's merger with Horizon Space Acquisition II Corp. and a $7.8 million PIPE financing. The wide trading range of $3.00 to $21.05 and volume of 3.93 million shares—far above the average of 487,860—underscore the speculative nature of the stock's movement.
SPAC Merger and PIPE Financing
SL Science began trading under the ticker SLBT after completing its merger with Horizon Space Acquisition II Corp., as disclosed in a June 15 Form 6-K. The company also announced a $7.8 million PIPE (private investment in public equity) to support its operations. The PIPE deal involved the issuance of ordinary and preferred shares, with preferred shares converting into one-third of a common share after six months, subject to a six-month lock-up period. The lock-up expiration could introduce additional share supply, potentially pressuring the stock.
Clinical Pipeline and Valuation
SL Science is focused on developing an off-the-shelf Gamma delta T cell therapy for solid tumors, including pancreatic and brain cancers. These therapies are designed to be produced at scale and used without patient-specific customization. CEO William Wang described the Nasdaq listing as a transformative milestone. The company's implied equity value stands at $5.568 billion, a figure that stands in stark contrast to the modest $7.8 million PIPE, raising questions about valuation relative to the company's stage of development.
Market Dynamics and Risks
The recent price action appears to be driven by technical factors—low float, high volatility, and momentum trading—rather than new clinical data. The company's filings highlight significant risks, including challenges in hitting development targets, completing clinical trials, obtaining regulatory approvals, and realizing merger benefits. With no analyst coverage and limited audited financials, the stock is trading more like a post-SPAC speculative bet than a fundamentally valued equity.
Investor Outlook
Investors are now looking for clarity on clinical timelines, regulatory filings, and the company's cash runway. The focus is also on the expiration of the PIPE lock-up and potential new share supply. Long-term holders await concrete milestones to justify the current valuation, while bears point to the lack of audited numbers, missing trial results, and the absence of analyst coverage as reasons for caution. Until more substantive data emerges, SLBT remains a high-risk, momentum-driven play.
